课题基金 / 基金详情

Cancer Immune Monitoring and Analysis Center

Cancer Immune Monitoring and Analysis Center
癌症免疫监测分析中心
批准号:
10730296
负责人:
FRANK S HODI
金额:
$197.39万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
未结题
起止时间:
2017-09-30 至 2028-06-30
关键词:
AccelerationAddressAdoptive Cell TransfersAllogenicAntigensAutomobile DrivingBiologicalBiological AssayBiological MarkersBiologyBloodBlood specimenCancer Therapy Evaluation ProgramCellsClinicalClinical TrialsClone CellsCollaborationsCommunicationComplexCoupledDana-Farber Cancer InstituteDataData AnalysesData SetDetectionDevelopmentEpitopesEvaluationFosteringGenomicsGoalsImmuneImmune responseImmunologic MonitoringImmunooncologyImmunotherapeutic agentImmunotherapyIndividualInstitutionKnowledgeLaboratoriesLearningLinkLongevityMachine LearningMalignant NeoplasmsMethodsMissionModalityMonitorMotivationMovementMultiomic DataOncolytic virusesPatientsPerformancePeripheralPhasePhenotypePopulationPrincipal InvestigatorProcessProtocols documentationRadiation therapyRecording of previous eventsResearchResistanceResourcesRoleSeriesSiteSpecimenStainsStandardizationStem cell transplantT-Cell Immunologic SpecificityT-Cell ReceptorT-LymphocyteT-cell receptor repertoireTestingTherapeuticTissue SampleTissuesToxic effectUnited States National Institutes of HealthVaccine TherapyValidationVariantWorkWritingbioinformatics toolbiomarker identificationcancer cellcancer immunotherapycancer therapycancer typechimeric antigen receptor T cellscomputerized data processingcomputerized toolsdata integrationdata standardsdesignflexibilityhigh dimensionalityimaging modalityimmune checkpoint blockadeimmunotherapy clinical trialsimmunotherapy trialsimprovedinnovationinter-institutionalinvestigator-initiated trialmolecular markermultiple omicsnovelnovel strategiesnovel therapeuticspatient subsetspersonalized cancer therapyprocess improvementprogramsresponseresponse biomarkersingle cell analysisstandard of caresuccesstherapy resistanttooltool developmenttranscriptomicstreatment responsetumortumor microenvironmenttumor-immune system interactionswasting

项目摘要

项目成果

FRANK S HODI的其他基金

相似基金

相关文献

中文摘要
翻译
总结
英文摘要
Summary Because cancer immunotherapy constitutes one of the most transformative therapeutic movements over the history of cancer treatment, there are now hundreds, if not thousands, of ongoing clinical trials in this field. Despite the remarkable success for a subset of patients, there are substantial gaps in our knowledge. No more than 30% of patients respond to immune checkpoint blockade and related therapies, many responding patients develop therapeutic resistance, and many responding and non-responding patients suffer from immune-related toxicities. There is a clear need to identify critical biomarkers of response, resistance, and toxicity. To improve our ability to meet this challenge, the NCI-sponsored Cancer Immune Monitoring and Analysis Center (CIMAC) program was created to enable consistent and comparable interrogation of patient biospecimens across multiple clinical trials. The program has successfully established a common set of assays harmonized across the four CIMACs, augmented this basic set with more specialized tests that may be CIMAC-specific but are still accessible across institutions, deployed these tools across dozens of phase I/II immunotherapy trials, and generated a pool of standardized data to facilitate inter-trial comparisons. The CIMAC created at Dana-Farber Cancer Institute (DFCI) built on the existing Center of Immuno-Oncology (CIO) and the long-standing collaboration with the Broad Institute of MIT and Harvard. The DFCI/Broad CIMAC, joining with the other CIMACS, now proposes to continue the network mission to compare tumor and immune response features of individual cancer types treated by multiple immunotherapeutic modalities and multiple cancer types treated by a single immunotherapeutic modality in order to dissect common and individualized mechanisms of action. One driving motivation for this renewal application is that the power to identify biomarkers increases with the number of clinical trials analyzed. Thus, Aim 1 focuses on deploying the suite of assays established over the past five years to biospecimens collected from additional innovative immunotherapy clinical trials to standardize biomarker analysis and interpretation. To broaden the scope of parameters being examined, Aim 2 proposes to develop and verify performance for novel and more complex assays to expand the network capabilities and advance discovery. Of particular value will be methods that improve multiomic single cell profiling, multiomic spatial analysis, and immunopeptidome characterization. Aim 3 addresses the challenge of integrating multiomic data across an increasing number of clinical trials by building novel computational tools that can efficiently process massive amounts of data and generate interpretable representations of the results. Altogether, these efforts will support the role of immuno-oncology in the personalized treatment of cancer because only by the analyses of large well-annotated datasets can we identify links between biology, molecular markers and clinical response.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.xpro.2022.101163
发表时间: 2022-03-18
期刊: STAR protocols
影响因子: --
作者: [Hallisey M, Dennis J, Abrecht C, Pistofidis RS, Schork AN, Lightbody ED, Heilpern-Mallory D, Severgnini M, Ghobrial IM, Hodi FS, Baginska J]
通讯作者: Baginska J
Simplified mass cytometry protocol for in-plate staining, barcoding, and cryopreservation of human PBMC samples in clinical trials.
在临床试验中,用于人类PBMC样品的板内染色,条形码和冷冻保存的简化质量细胞仪方案。
DOI: 10.1016/j.xpro.2022.101362
发表时间: 2022-06-17
期刊: STAR PROTOCOLS
影响因子: --
作者: [Abrecht, Charlotte, Hallisey, Margaret, Dennis, Jenna, Nazzaro, Matthew, Brainard, Martha, Hathaway, Emma, Schork, Abigail N., Hodi, Stephen, Severgnini, Mariano, Baginska, Joanna]
通讯作者: Baginska, Joanna
3D Models of Immunotherapy
  • 批准号:
    9283025
  • 项目类别:
  • 资助金额:
    $57.44万
  • 财政年份:
    2017
  • 负责人:
    FRANK S HODI
  • 依托单位:
3D Models of Immunotherapy
  • 批准号:
    9896778
  • 项目类别:
  • 资助金额:
    $55.68万
  • 财政年份:
    2017
  • 负责人:
    FRANK S HODI
  • 依托单位:
Bevacizumab plus Ipilimumab in Unresectable Stage III or Stage IV Melanoma
  • 批准号:
    8081790
  • 项目类别:
  • 资助金额:
    $32.32万
  • 财政年份:
    2010
  • 负责人:
    FRANK S HODI
  • 依托单位:
Bevacizumab plus Ipilimumab in Unresectable Stage III or Stage IV Melanoma
  • 批准号:
    7892847
  • 项目类别:
  • 资助金额:
    $33.24万
  • 财政年份:
    2010
  • 负责人:
    FRANK S HODI
  • 依托单位:
海外基金